FDA action on GLP-1 combinations

By Dr Nicola Davies

The US Food and Drug Administration’s (FDA) recent moves around GLP-1-based combination therapies are telling, not just about the agency’s evolving stance on obesity treatment, but about how it is reshaping its regulatory playbook for metabolic disease.

The focus is shifting from siloed indications to integrated strategies that reflect the overlapping pathophysiology of obesity and type 2 diabetes (T2D). For pharma professionals working in metabolic disease, the agency’s actions are more than a signal, they are a strategic imperative.